Premium
Multiple‐dose pharmacokinetics of cefpirome in long‐term hemodialysis with high‐flux membranes
Author(s) -
Thalhammer Florian,
Schmaldienst Sabine,
Elmenyawi Ibrahim,
Atteneder Martin,
Burgmann Heinz,
Hollenstein Ursula,
Georgopoulos Apostoulos,
Graninger Wolfgang,
Putz Dina,
Rosenkranz Alexander R.,
Mayer Gert,
Hörl Walter H.,
Breyer Stefan
Publication year - 1996
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/s0009-9236(96)90212-x
Subject(s) - cefpirome , pharmacokinetics , hemodialysis , medicine , half life , urology , cephalosporin , pharmacology , antibiotics , chemistry , biochemistry , antibiotic resistance , imipenem
Cefpirome is a cephalosporin eliminated primarily by kidneys that requires dosage reduction in patients with renal failure. The pharmacokinetic parameters were studied in 10 patients with end‐stage renal disease who were receiving hemodialysis. Repeated intravenous administration of 2 gm cefpirome three times a week resulted in trough levels of 12.2 ± 5.4 μg/ml and peak serum concentrations of 99.6 ± 82.1 μg/ml. After 312 hours of hemodialysis with polysulfone high‐flux membranes, 62.3% ± 23.3% of cefpirome was removed. The interdialytic half‐life was 9.35 ± 0.99 hours, and the intradialytic half‐life was 2.02 ± 0.7 hours. Clinical Pharmacology & Therapeutics (1996) 60 , 645–650; doi: